earnings
confidence high
sentiment positive
materiality 0.85
Agios reports Q3 net income of $947.9M on $1.1B milestone payments; PYRUKYND rev $9.0M
AGIOS PHARMACEUTICALS, INC.
2024-Q3 EPS reported
$13.38
revenue$25,768,000
- Net income $947.9M vs loss $91.3M YoY; driven by $1.1B payments from Royalty Pharma & Servier.
- PYRUKYND net revenue $9.0M (+4% QoQ); 127 patients on therapy, 211 enrollment forms.
- Completed enrollment of Phase 3 RISE UP for mitapivat in SCD; topline data expected late 2025.
- Initiated Phase 2b of tebapivat in LR-MDS; FDA orphan drug designation for MDS received.
- Cash, equivalents and securities $1.7B at Sept 30, 2024, up from $806.4M at Dec 31, 2023.